These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39139778)

  • 41. Medicaid expansion and opioid deaths.
    Averett SL; Smith JK; Wang Y
    Health Econ; 2019 Dec; 28(12):1491-1496. PubMed ID: 31762149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
    Scott CK; Grella CE; Dennis ML; Carnevale J; LaVallee R
    Health Justice; 2022 Dec; 10(1):36. PubMed ID: 36538121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement: A Randomized Clinical Trial.
    McNeely J; Wang SS; Rostam Abadi Y; Barron C; Billings J; Tarpey T; Fernando J; Appleton N; Fawole A; Mazumdar M; Weinstein ZM; Kalyanaraman Marcello R; Dolle J; Cooke C; Siddiqui S; King C
    JAMA Intern Med; 2024 Sep; 184(9):1106-1115. PubMed ID: 39073796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment setting among individuals with opioid use and criminal legal involvement, housing instability, or Medicaid insurance, 2015-2021.
    Shearer RD; Howell BA; Khatri UG; Winkelman TNA
    Drug Alcohol Depend Rep; 2023 Sep; 8():100179. PubMed ID: 37502021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
    Walley AY; Lodi S; Li Y; Bernson D; Babakhanlou-Chase H; Land T; Larochelle MR
    Addiction; 2020 Aug; 115(8):1496-1508. PubMed ID: 32096908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. US payment policy for medications to treat opioid use disorder: landscape and opportunities.
    McGinty EE; White SA; Eisenberg MD; Palmer NR; Brown CH; Saloner BK
    Health Aff Sch; 2024 Mar; 2(3):qxae024. PubMed ID: 38756918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 51. Mobile addiction treatment and harm reduction services as tools to address health inequities: a community case study of the Brockton Neighborhood Health Center mobile unit.
    Pinkhover A; Celata K; Baker T; Chatterjee A; Lunze K
    Front Public Health; 2024; 12():1407522. PubMed ID: 38957203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
    Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
    PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
    Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medicaid expansion and drug overdose mortality during the COVID-19 pandemic in the United States.
    Auty SG; Griffith KN
    Drug Alcohol Depend; 2022 Mar; 232():109340. PubMed ID: 35131533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Access to Services for Pregnant People With Opioid Use Disorder in Jails in the United States.
    Grella CE; Scott CK; Dennis ML; LaVallee RA
    J Correct Health Care; 2023 Aug; 29(4):299-307. PubMed ID: 37252747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of medication for opioid use disorder treatment during a natural disaster: The PROUD-LA study.
    Springgate B; Matta I; True G; Doran H; Torres WV; Stevens E; Holland E; Mott K; Ardoin TR; Nixdorff N; Haywood C; Meyers D; Johnson A; Tatum T; Palinkas LA
    J Subst Use Addict Treat; 2024 Oct; 165():209469. PubMed ID: 39094901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Intern Med; 2024 Aug; 184(8):954-962. PubMed ID: 38884975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.